News
Filter news type:
Filter by year:
See events

New studies evaluate the performance of the VirClia® Galactomannan test in the diagnosis of aspergillosis

  • Posters TIMM 2025_1
  • Posters TIMM 2025_1

New studies evaluate the performance of the VirClia® Galactomannan test in the diagnosis of aspergillosis

During the Trends in Medical Mycology (TIMM 2025) congress, held in Bilbao, two new scientific evaluations were presented on the Aspergillus Galactomannan Ag VirClia® Monotest, a fully automated chemiluminescent immunoassay designed for the rapid detection of the galactomannan antigen.

  • P163 – New frontiers for the Aspergillus galactomannan antigen test: VirClia chemiluminescence immunoassay performance in the diagnosis of Aspergillosis

    The study evaluated 255 samples (197 serum and 58 bronchoalveolar lavage, BAL), comparing the performance of the VirClia® Galactomannan assay with the reference method Platelia® Aspergillus Ag (BioRad).

    The results showed excellent agreement of 88% in serum and 100% in BAL, with sensitivity above 95% and high specificity in both matrices. Thanks to its speed, ease of use, and single-sample processing, the authors concluded that the VirClia® Galactomannan test can be reliably used for the detection of the galactomannan antigen in patients with invasive fungal infections.

  • P171 – Evaluation of the Virclia Aspergillus GM Monotest

    A retrospective study of 369 samples (162 serum/plasma and 207 bronchoalveolar lavage fluid, BALF) assessed the clinical and analytical performance of the VirClia® Galactomannan assay compared with the BioRad test across different forms of aspergillosis: invasive (IA), chronic (CPA), and virus-associated (IAPA/CAPA).

    The study reported a sensitivity of 92% and specificity of 76% in BALF, compared to 40% and 100% respectively in blood. For IA and IAPA/CAPA cases, sensitivity reached 100% in BALF. The authors highlighted that the VirClia® monotest format enables urgent testing in laboratories with lower sample throughput, providing results in under one hour with full automation.

Both studies, presented during TIMM 2025, reinforce the clinical value of the VirClia® Galactomannan Monotest as a high-performance, flexible diagnostic tool for the rapid detection of aspergillosis across diverse clinical settings.